Major Depressive Disorder (MDD) Clinical Trial
Official title:
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
Existing drug and talking therapies for major depressive disorder (MDD) fail to produce complete recovery. This study will determine if substantial improvements to one of the most promising therapies, cognitive therapy (CT), can be achieved by administering a carefully designed procedure to improve memory for the content of CT sessions. This is important because (a) memory deficits are common in MDD patients and (b) each CT therapy session typically covers a complex array of topics and various skills are taught.
Background. Major depressive disorder (MDD) is one of the most prevalent psychiatric
disorders and a leading cause of disability worldwide. Existing therapies fail to produce
complete recovery. Progress toward improving outcome must include innovations that are safe,
powerful, inexpensive and simple (for fast and effective dissemination). The proposed
research seeks to test one such innovation. We seek to improve outcome by improving memory
for the content of cognitive therapy (CT) sessions. CT is one of the most promising
approaches to the treatment of MDD, yet there is room for improvement.
We believe that adding memory enhancing strategies to CT may improve MDD outcome because:
(a) MDD is often characterized by memory impairment, (b) there is evidence that the memory
impairment is modifiable, (c) CT typically entails the activation of emotion, (d) emotion
can impair or bias memory and (e) there is evidence that memory for the content of therapy
sessions is poor.
Aim. To evaluate if a strategy designed to enhance memory for the content of CT sessions
improves treatment outcome for MDD. Cognitive support involves a series of specific
procedures that support the encoding and retrieval stages of an episodic memory. It is
hypothesized that CT+Cognitive Support, relative to CT-as-usual, will be associated with
improved depression outcome at the end of treatment and 6 months after the completion of
treatment.
Research Plan. A small pilot feasibility RCT will be conducted on adults with MDD (n = 48)
who will be randomized to one of two groups: (a) CT+Cognitive Support (n = 24) or (b)
CT-as-usual (n = 24). Outcome measures will be taken at baseline, end of treatment, and 6
months after treatment. Long-term objective. To provide the pilot data needed to prepare a
larger scale intervention study focused on improving outcomes by improving memory for the
content of therapy sessions. The outcomes, if positive, will have major public health
implications because simple, inexpensive memory enhancing strategies can be readily included
as a standard feature in all psychosocial treatments for a broad range of mental illness.
Project
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 | |
Completed |
NCT05416957 -
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
|
Phase 1 | |
Active, not recruiting |
NCT03642964 -
A Study in Patients With Major Depressive Disorder
|
Phase 2 | |
Terminated |
NCT01111565 -
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Completed |
NCT01912196 -
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
|
Phase 2 | |
Completed |
NCT00958204 -
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
|
Phase 3 | |
Completed |
NCT00102492 -
Study Of GW679769 In Major Depressive Disorder
|
Phase 2 | |
Completed |
NCT02012218 -
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
|
Phase 3 | |
Completed |
NCT01477203 -
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
|
Phase 4 | |
Completed |
NCT00768430 -
Optimization of IV Ketamine for Treatment Resistant Depression
|
Phase 2 | |
Completed |
NCT00559299 -
Patient Tolerability Study of GSK163090
|
Phase 1 | |
Terminated |
NCT01123707 -
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Completed |
NCT04403373 -
Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study
|
N/A | |
Completed |
NCT05541302 -
Retrospective TMS Therapy for Adults With MDD
|
||
Recruiting |
NCT06385405 -
Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment
|
N/A | |
Completed |
NCT00330616 -
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
|
Phase 2 | |
Recruiting |
NCT03012724 -
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
|
N/A | |
Completed |
NCT02380066 -
Comparison of Anyu Peibo With Placebo in Treatment of MDD
|
Phase 2 | |
Not yet recruiting |
NCT02395263 -
Comparison of Yuxintine With Placebo in Treatment of MDD
|
Phase 2 | |
Completed |
NCT01187407 -
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
|
Phase 3 |